SNY
6:00 AM
ESCMID: Sanofi’s NUVAXOVID™ COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
Trial Results • Phase 4sanofi.com
News Updates
Sat, Apr 18, 2026
1 updatesSat, Mar 28, 2026
1 updatesSNY
11:00 AM
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Trial Results • Phase 3sanofi.com